Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XanaCIDD: a Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem in Adults with Major Depressive Disorder and Impaired Cognition

Next Previous
Trial Profile

XanaCIDD: a Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem in Adults with Major Depressive Disorder and Impaired Cognition

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emestedastat (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms XanaCIDD
  • Sponsors Actinogen Medical

Most Recent Events

  • 02 Feb 2026 According to an Actinogen Medical media release, the company expects to announce the publication of the results of its XanaCIDD phase 2a major depressive disorder trial in a peer-reviewed journal during the coming months.
  • 26 Aug 2024 According to an Actinogen Medical media release, company will discuss depression data and trial results findings about Xanamem's cortisol control mechanism in a webinar at 11am (AEST) on Thurs, Aug 29 or 9pm (US ET) on Wed, Aug 28.
  • 26 Aug 2024 Results published in an Actinogen Medical media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top